- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
John N. Allan, MD | Authors
Articles
John N. Allan, MD, on the Impact of First-Line Ibrutinib in Patients with CLL, TP53 Aberrations
December 07, 2020
This pooled analysis from 4 clinical trials suggested that though patients with TP53 aberrations remain at risk for progression, first-line treatment with ibrutinib has meaningfully improved the poor prognosis in this high-risk population.
John N. Allan, MD, on Research Coming Out of ASH for CLL
December 05, 2020
The assistant professor of Medicine in the division of Hematology and Medical Oncology at Weill Cornell Medicine spoke about exciting research coming out of ASH for patients with chronic lymphocytic leukemia.